Yazar "Saka, Guenay" seçeneğine göre listele

Listeleniyor 1 - 2 / 2
  • [ X ]
    Öğe
    The epidemiological aspects of fibromyalgia syndrome in adults living in turkey: A population based study
    (Taylor & Francis Ltd, 2008) Turhanoglu, Ayse Dicle; Yilmaz, Serif; Kaya, Sedat; Dursun, Mehmet; Kararmaz, Alper; Saka, Guenay
    Objective: The objectives of this study were to determine the prevalence of the fibromyalgia syndrome [FMS] in Diyarbakir, a city located in the southeastern region of Turkey, and to evaluate associated demographic variables. Methods: This study was conducted in the beginning of 2003. A total of 600 people, randomly selected by stratified cluster sampling, were interviewed in person using a questionnaire consisting of demographic features and history of chronic widespread pain. Individuals with chronic widespread pain were examined by a specialist in physical medicine and rehabilitation in order to confirm or exclude FMS based on the American College of Rheumatology classification criteria. The statistical analysis was performed by using a package program called Epi Info 2000. Results: Fifty-three people were diagnosed with FMS. Based on the study results, the prevalence of FNIS was 8.8 percent in our regional study group. The prevalence was higher in women [12.5 percent] than in men [5.1 percent; P = 0.002, OR = 3.038, 95% CI = 1.5-6.1], and subjects in urban areas [11.4 percent] had a higher FMS rate than subjects in rural areas [5.2 percent; P = 0.011, OR = 2.388, 95% CI = 1.2-4.6]. The FMS was most common in the 50- to 59-year-old age group. No difference was observed in terms of education, occupation, and marital status. Conclusion: To the best of our knowledge, this cross-sectional study is the first report on the prevalence of FMS in Diyarbakir. The FMS prevalence was 8.8 percent in our region. The FMS was found 2.45 times more common in women than in men and found 2.3 times higher in urban areas than in rural areas.
  • [ X ]
    Öğe
    Long-term conventional interferon alpha in combination with lamivudine for chronic hepatitis B: Data from Turkey
    (H G E Update Medical Publishing S A, 2007) Yilmaz, Serif; Bayan, Kadim; Dursun, Mehmet; Canoruc, Fikri; Pasa, Semir; Saka, Guenay
    Background/Aims: Standard interferon or lamivudine monotherapy has been shown to induce a low response rate in patients with chronic hepatitis B infection. Genotype D represents almost the whole of chronic HBV infection of Turkish population. The aim of this study was to evaluate the efficacy and safety of the long-term interferon-alpha plus lamivudine on these patients, and thereafter the co-effect of maintenance therapy by lamivudine. Methodology: This prospective study was carried out between the late 1999 and 2005. A total of 37 (24 HBeAg-positive and 13 HBeAg-negative) patients were enrolled in the study. These patients received standard interferon-alpha (9/10 MU) three times sc. a week plus lamivudine 100mg po. daily, for 52 weeks. After the interferon discontinuation, lamivudine monotherapy was assigned to be given until 4-6 months after the occurrence of HBeAg seroconversion in the HBeAg-positive patients and at least three years in HBeAg-negative patients. Response-1 was defined as the response at the end of combination therapy at the 52nd week, and Response-2 as response at the end of the follow-up period under lamivudine monotherapy. An intention-to-treat analysis was performed. Results: Patients' follow-up ranged between 7-67 months, with a mean duration of 29.64 +/- 14.01 months. Twenty-six patients (70.3%) had a Response-1, both virological and biochemical. A biochemical Response-2 was achieved in 24 patients (64.9%), while virological Response-2 in 17 (45.9%). Response-1 and Response-2 were similar between HBeAg-positive and HBeAg-negative patients (p=0.262 and p=0.734, respectively). HBeAg seroconversion was achieved only in 8 (33.3%) of HBeAg-positive patients. Clinical resistance to lamivudine developed only in 9 (24.3%) of the patients. Decompensation or hepatocellular carcinoma did not observe in any case. Conclusions: This study showed the efficacy of the 'long-term' anti-viral maintenance along with the combination therapy in genotype D predominant chronic hepatitis B patients. A low clinical resistance rate to lamivudine was achieved.